11月22日是小雪节气。小雪时节适宜吃些什么？如何进行日常保健？让我们通过海报，了解一下小雪时 节的养生知识。 外出晨练时间不宜过早，日出后为宜，可到阳 光充足、避风处锻炼;运动前充分热身,防止 关节损伤;避免大汗淋漓的剧烈运动,推荐项 目有八段锦、太极拳、室内瑜伽或散步等。 疾病预防勿轻视 预防心脑血管疾病。 气温骤降易致血管收缩， 高血压患者应启时监测血压;冠心病患者要注 意保暖,随身携带急救药物。 预防呼吸道疾病。外出佩戴口罩,勤洗手,避 免前往人群密集场所,易感人群可提前服用预 防类药物以固表防感。 适量进食羊肉、牛肉、鸡肉、深海鱼等温热食 材,可搭配黄芪、当归、生姜等炖煮,有改善 畏寒肢冷等功效。减少食用西瓜、苦瓜等寒凉 食物,辣椒、胡椒等辛辣食材,避免损伤脾 育。 动静结合蓄能量 记者：高爽 ...

Core Viewpoint - Yulong County is leveraging its rich ecological resources to develop a unique traditional Chinese medicine (TCM) industry, focusing on sustainable practices and innovative models to enhance both economic and ecological benefits [1][3]. Group 1: Ecological and Economic Synergy - Yulong County is transforming its limited arable land into new opportunities for TCM by utilizing its abundant forest resources, with a forest coverage rate exceeding 68.24% [1][3]. - The county is implementing a "forest + organization + cooperative + company + farmer" model to promote the cultivation of high-quality TCM, effectively utilizing idle forest land while minimizing chemical fertilizer and pesticide use [3]. - The introduction of the "National Reserve Forest + N" project aims to innovate the development model of national reserve forests, enhancing TCM quality and establishing Yulong as a comprehensive industrial demonstration zone [3]. Group 2: Initial Processing and Economic Stability - Yulong County is addressing land use constraints by establishing "field-side" initial processing sites, which allow for local processing of TCM while protecting the ecological environment [4][7]. - Currently, Yulong County has built 10 initial processing sites, processing 52,100 tons of TCM annually, generating a processing output value of 2.16 billion yuan [7]. Group 3: Digital Transformation in the TCM Industry - The "Smart Cloud Medicine" industrial park was inaugurated to create a digital platform that integrates various stages of the TCM supply chain, from seedling breeding to market sales [10]. - The platform provides precise services across the supply chain, attracting investments from external enterprises and enhancing the local TCM industry [10]. - Yunnan Baiyao Group is advancing its digital transformation by establishing comprehensive management systems for various TCM plants, supporting breeding improvements and precise raw material matching for different medicinal needs [10][11].

Core Viewpoint - The traditional Chinese medicine (TCM) industry in China is experiencing rapid growth, with a market size exceeding 700 billion yuan, but faces challenges such as high planting costs and quality control issues, necessitating an urgent need for a comprehensive upgrade of the entire industry chain [1] Industry Development - Gansu Province, particularly Dingxi City, is a key area for TCM resources, with a stable planting area of over 2 million mu and a total output of more than 500,000 tons [1] - The TCM industry is a strategic pillar for Dingxi, contributing significantly to local income, with farmers earning 22.4% of their disposable income from TCM-related activities [1] Standardization and Efficiency - Dingxi has implemented standardized planting practices, significantly reducing labor costs from one-third to one-tenth of income through mechanization and drone technology [3] - The establishment of a closed-loop system for quality control in TCM planting has been achieved, with 84.2% of TCM being standardized [4] Quality Assurance - Efforts to ensure the quality of TCM materials include the establishment of seed processing plants and the promotion of high-quality seed varieties, resulting in a germination rate of over 98% [4] - The introduction of the "GAP" (Good Agricultural Practices) standard has led to the establishment of 33.02 million mu of compliant TCM bases in Gansu, maintaining a leading position nationally [8] Market and Trade - Dingxi's TCM market has a static storage capacity of 1.4 million tons, with annual trading volumes exceeding 150 million tons and transaction values nearing 30 billion yuan [12] - The establishment of processing workshops and the integration of TCM production and trade have enhanced local economic benefits, with companies like Gansu Tianceng Xingwei Pharmaceutical Co., Ltd. leading the way in the full industry chain development [7][14] Innovation and Product Development - Companies are increasingly focusing on the development of health products, with Gansu Weishuiyuan Pharmaceutical Technology Co., Ltd. expanding its product line to include health series products, contributing to 10% of its sales revenue [15] - The introduction of AI technology in production processes has improved efficiency by 50%, allowing for precise control over product quality [15] Investment and Future Prospects - Recent trade fairs have resulted in significant investment agreements, with 68 projects signed worth 8.966 billion yuan, indicating strong future growth potential in the TCM sector [16]

Core Viewpoint - The tax authorities in Gansu's Dangchang County are actively providing tailored tax services to local herbal farmers, enhancing their confidence and operational efficiency in the medicinal herb industry, thereby contributing to the economic development of the region [1][2][3][4]. Group 1: Tax Services and Support - Tax officials are directly engaging with farmers to explain tax policies and assist with invoicing, which has improved the connection between farmers and buyers [2]. - The tax department offers one-on-one guidance to cooperatives, helping them understand tax exemptions and financial regulations, allowing them to focus on product quality [3]. - A "convenient service point" has been established in the market to assist small taxpayers and e-commerce entities with invoicing, ensuring smooth transaction flows [3][4]. Group 2: Economic Impact and Growth - The implementation of tax exemptions and support services has led to increased confidence among farmers, with reported earnings of 100,000 yuan from medicinal herb cultivation last year [2]. - The tax department's assistance has enabled local enterprises to benefit from tax reductions, facilitating their expansion into deeper processing of medicinal herbs [4]. - The overall strategy aims to transform the local herbal industry into a significant contributor to rural revitalization and income generation for the community [4].

Core Insights - The article discusses the natural phenomenon of hair loss in autumn, attributing it to the body's adaptation to seasonal changes and the need for energy conservation [1][2] - It emphasizes the importance of holistic approaches to hair care, including diet, emotional well-being, and sleep, in order to maintain healthy hair during the autumn season [3][5][6] Group 1: Seasonal Changes and Hair Loss - The article explains that as autumn arrives, the body's yang energy shifts inward, leading to reduced nourishment for hair, which results in natural hair loss [2] - It notes that a normal daily hair loss rate is between 50 to 70 strands, but significant increases may require medical attention [2] Group 2: Dietary Recommendations - The article suggests that nourishing the liver and kidneys is essential for hair health, recommending foods like black sesame, black beans, and walnuts to support kidney function [3] - It also highlights the benefits of foods such as yam, lily bulb, and lotus root for lung health, which can indirectly support hair vitality [3] Group 3: Scalp Care Techniques - The article introduces scalp massage techniques to enhance blood circulation and promote hair nourishment, recommending specific movements and pressure points [4] - It advises daily scalp brushing and pressure application on key acupressure points to stimulate energy flow [4] Group 4: Emotional and Sleep Health - The article stresses the importance of emotional stability in maintaining hair health, suggesting activities like music, calligraphy, and socializing to improve mood [5] - It emphasizes the significance of sleep, particularly during specific hours, to support liver health and consequently hair growth [6] Group 5: Herbal Remedies - The article proposes a herbal wash using ingredients like cedar leaves and ginger to aid in hair health, recommending this treatment two to three times a week [8] - It also suggests combining external herbal treatments with internal remedies for enhanced effectiveness, under professional guidance [8]

Core Viewpoint - Sichuan Xinhehua Traditional Chinese Medicine Co., Ltd. has submitted its prospectus to the Hong Kong Stock Exchange for the second time after its initial attempt in April 2023 failed, marking the fifth attempt by founder Jiang Yun to take the company public after 14 years of efforts in the IPO marathon [1][4]. Company Overview - Founded in 2001, Sichuan Xinhehua has been deeply engaged in the traditional Chinese medicine (TCM) sector for 24 years, focusing on the research, production, and sales of both toxic and non-toxic TCM pieces, with a product matrix of 770 types [1]. - The company ranks second in the national TCM market with a market share of 0.4% based on projected revenue for 2024, and its products are exported to markets such as Vietnam and Malaysia [1]. Ownership Structure - The company exhibits a typical family-controlled structure, with founder Jiang Yun holding 31.5% directly and controlling an additional 15.6% through Guojia Investment, totaling 47.1% ownership [2]. - Family members are actively involved in management, with Jiang Yun's son, Jiang Ercheng, serving as Executive Director and Deputy Director of R&D [2]. IPO Attempts - Sichuan Xinhehua has made multiple attempts to go public, starting with its first application to the Shenzhen Stock Exchange in March 2011, which was voluntarily withdrawn in August 2012 [3]. - The company made a second attempt in 2020, but withdrew its application in April 2021 due to market conditions [3]. - In October 2023, the company initiated a new application for the Shenzhen Stock Exchange but voluntarily terminated the process in April 2024 [3]. Financial Performance - The company's revenue has grown from 780 million yuan in 2022 to 1.249 billion yuan in 2024, representing a cumulative growth of 60.1% over three years, although the growth rate has slowed significantly [4]. - Profit figures for 2022, 2023, and 2024 were 77.39 million yuan, 104 million yuan, and 89.11 million yuan respectively, with the decline in 2024 attributed to rising raw material costs and management expenses [5].

Core Viewpoint - New Lotus is one of the largest suppliers of traditional Chinese medicine (TCM) herbal pieces in China, ranking second in the market with a 0.4% market share and a compound annual growth rate (CAGR) of 27% from 2022 to 2024 [2][3] Company Overview - New Lotus operates a dual-pillar strategy, focusing on both the core TCM market and modern consumer-oriented solutions, serving over 1,000 hospitals and large pharmacy chains while also tapping into retail market growth [2] - The company is expanding its global presence through herbal product exports and establishing localized operations in high-potential international markets [2] Market Potential - The TCM herbal pieces market is projected to reach RMB 306.7 billion in 2024, making it the fastest-growing segment in the pharmaceutical industry [3] - New Lotus offers over 770 types and 4,900 categories of herbal pieces, with significant contributions from toxic pieces like Ban Xia and common pieces like Chuan Bei Mu and Dang Gui [3] Financial Performance - Revenue figures for New Lotus are as follows: - 2022: RMB 780.4 million - 2023: RMB 1,145.6 million - 2024: RMB 1,249.4 million - First half of 2024: RMB 598.7 million - First half of 2025: RMB 633.5 million [4] - Profit figures for the same periods are: - 2022: RMB 77.4 million - 2023: RMB 104.0 million - 2024: RMB 89.1 million - First half of 2024: RMB 42.7 million - First half of 2025: RMB 51.2 million [4]

Core Viewpoint - Sichuan Xinhehua Traditional Chinese Medicine Decoction Pieces Co., Ltd. has submitted an application for listing on the Hong Kong Stock Exchange, with GF Securities (Hong Kong) and Agricultural Bank of China International as joint sponsors [1] Company Overview - Xinhehua is one of the largest suppliers of traditional Chinese medicine decoction pieces in China, ranking second in the market with a 0.4% market share as of 2024, according to Frost & Sullivan [4] - The company is the fastest-growing among the top five market participants, with a compound annual growth rate (CAGR) of 27% in revenue from 2022 to 2024 [4] Business Strategy - The company employs a dual-pillar strategy that balances its leadership in the core traditional Chinese medicine market with rapid response solutions for modern consumers [4] - Xinhehua serves over 1,000 hospitals and medical institutions, as well as large chain pharmacies, small pharmacies, clinics, and operators through offline channels [4] - The company aims to tap into global opportunities by exporting herbal products and establishing localized operations in high-potential international markets [4] Market Potential - The market for traditional Chinese medicine decoction pieces is projected to reach RMB 306.7 billion in 2024, making it the fastest-growing segment in the pharmaceutical industry [5] - Xinhehua's revenue comes from over 770 types and 4,900 categories of decoction pieces, with significant contributions from toxic decoction pieces such as Banxia and Jiangbanxia, as well as common decoction pieces like Chuanbeimu, Maidong, and Danggui [5] Financial Performance - Xinhehua's revenue for the years ending December 31 for 2022, 2023, and 2024, as well as for the six months ending June 30, 2024, and 2025, is as follows: - 2022: RMB 780 million - 2023: RMB 1.145 billion - 2024: RMB 1.249 billion - 2024 (six months): RMB 599 million - 2025 (six months): RMB 633 million [5][6] - The company's profits for the same periods are: - 2022: RMB 77.4 million - 2023: RMB 104.0 million - 2024: RMB 89.1 million - 2024 (six months): RMB 42.7 million - 2025 (six months): RMB 51.2 million [5][6]

Core Insights - The traditional Chinese medicine (TCM) market is entering a critical period for production and sales, facing ongoing adjustments due to intensified supply-demand conflicts and strengthened policy guidance [1] Group 1: Supply and Demand Dynamics - The peak production period is expected to lead to a significant short-term increase in supply, with an estimated total production of approximately 5.8 million tons by 2025, while market demand is only about 5 million tons, resulting in an overall surplus rate of 16% [2] - The autumn harvest season in October will further highlight the supply-demand imbalance, leading to continued pressure on market prices [2] - Major varieties such as Angelica, Astragalus, and Codonopsis are expected to see a significant increase in supply as new crops are harvested [2] Group 2: Procurement Strategies and Price Adjustments - Under the backdrop of centralized procurement, TCM companies are adopting conservative procurement strategies to control raw material costs, with the second round of national centralized procurement for TCM decoction pieces already initiated [3] - This centralized procurement is expected to cover a wider range of products, prompting companies to reduce costs and improve efficiency through standardization, indicating a new round of price adjustments in the TCM industry [3] - The price bottoming trend for TCM materials may persist until the end of 2025 or even into 2026, particularly as root and rhizome materials are fully harvested [3] Group 3: Industry Transformation and Quality Standards - The TCM industry is accelerating its transformation, with initiatives like Zhejiang's "Zhejiang Eight Flavors" project aimed at establishing quality standards for TCM materials [4] - The implementation of Good Agricultural Practices (GAP) for TCM is being promoted nationwide to ensure quality, with various regions actively developing GAP bases [4] - Companies are increasingly focusing on establishing high-standard TCM planting bases to ensure the quality and traceability of authentic medicinal materials, which is crucial for building product barriers and advancing the modernization of TCM [5][6] Group 4: Long-term Industry Outlook - The TCM market is currently in a deep adjustment phase due to multiple factors, including production pressure, weak demand, capital withdrawal, and policy guidance [6] - The industry is expected to gradually move towards a path of standardization, branding, and quality improvement, with "high quality and high price" becoming the mainstream trend [6] - Industry participants are encouraged to adapt to policy directions and focus on high-quality and specialty varieties to seize opportunities in the ongoing industry restructuring [6]

Core Insights - The Chinese herbal medicine market is experiencing a significant price decline due to increased supply and weakened demand, marking a systemic adjustment across the industry [1][3][4] Price Trends - The average trading price of six major herbal medicines in Dingxi, Gansu Province, has dropped to 61.54 yuan per kilogram, a decrease of 1.07% from the previous week, continuing a six-week downward trend [2] - The price index for Sanqi has fallen to 135.94 points, down 30.9% from 196.77 points at the beginning of the year [2] - The overall Chinese herbal medicine price index has decreased by 28.5% since July 2024, reaching a new low of 1605.27 points [3] Supply and Demand Dynamics - The oversupply in the market is attributed to a significant increase in planting area driven by previous high prices, with an expected total output of 5.8 million tons against a demand of 5 million tons, resulting in a surplus rate of 16% [4][5] - The demand side is weak, with traditional Chinese medicine enterprises facing pressure from national procurement policies, leading to a conservative purchasing strategy [5] Market Behavior - Speculative trading in niche herbal products has led to drastic price corrections, with some products like Cat's Claw dropping over 90% from their peak prices [5] - Regulatory interventions and the implementation of quality management standards are reshaping the market, pushing non-compliant products out of formal channels [6][7] Future Outlook - The current price decline is expected to persist until at least the end of 2025, with further increases in low-priced varieties anticipated as production peaks [7]